Clinical Trials Search
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Primary Objective: To determine the optimal RP2D for LY3295668. Secondary Objectives: To assess the PK of LY3295668 administered as monotherapy, and to document preliminary signs of efficacy of LY3295668 administered as monotherapy. Tertiary/Exploratory Objectives: To assess the relationship between biomarkers and clinical outcome, to assess relationship between LY3295668 exposure and response in terms of safety (for example, ECG parameters) and efficacy, and to estimate the renal clearance of LY3295668 and conduct exploratory metabolite identification on blood and urine samples.